Clinical Study on the Effect of the Quadruple Regimen of Adjusted Bismuth Agent on Helicobacter Pylori
Objective:To observe the eradication effect of bismuth-adjusted quadruple regimen on Helicobacter pylori infection.Methods:90 CG patients diagnosed with Hp infection who underwent gastroscopy and histopathological examination from September 2020 to July 2021 were randomly assigned into three groups.Group A received the classic regimen for 14 days,Group B received bismuth potassium citrate for 14 days,and Group C received bismuth potassium citrate with the frequency and dose of quadruple therapy changed for 10 days plus bismuth potassium citrate monotherapy for 18 days.All patients underwent a 13C-UBT breath test to detect Hp infection,gastroscopy,and histopathological examination 4 weeks after treatment discontinuation.Results:A total of 90 patients were enrolled,among whom 85 patients completed the treatment.In ITT analysis,the overall eradication rate of Hp was 84.44％,and there was no significant difference among the 3 groups(x2=2.053,P=0.439).In PP analysis,the overall eradication rate of Hp was 89.41％,and there was no significant difference among the 3 groups(x2=2.874,P=0.229).There were significant differences in the effective remission rate of clinical symptoms and the incidence of adverse reactions among the three groups(x2=15.624,2.222;P＜0.001).After treatment,there was significant difference in histological chronic inflammation score among 3 groups(F=7.698,P=0.001).After treatment,there was statistically significant difference in the score of histological active inflammation among the 3 groups,with statistically significant difference(F=6.162,P=0.003).Conclusion:The combination dose of bismuth and PPI and the addition of bismuth single drug regimen does not reduce the eradication rate or increase the occurrence of adverse reactions.It can better improve clinical symptoms,histopathologic chronic inflammation and histopathologic active inflammation.
万方数据
维普
